Category: polyclonal

Name: BRG1 (EPNCIR111A)

Description and aplications: BRG1, also known as SMARCA4 or BAF190A, SNF2B and SNF2L4, is a member of the enzymatic chromatin remodeling complex SWI/SNF, where it encodes the catalytic subunit that intervenes in the configuration of nucleosomes, making the transcriptional activation of the complex more accessible. The gene encoding the protein is located in the chromosome region 19p13.2, whose alterations have primarily been associated with the rhabdoid tumor predisposition syndrome-2 and Coffin-Siris syndrome 4. The former is characterized by a predisposition to develop renal or extrarenal rhabdoid tumors as well as a variety of brain tumors among which are choroid plexus carcinoma, meduloblastoma and PNET. CoffinSiris syndrome 4 presents both autosomal recessive and dominant transmission and is characterized by intellectual disability, psychomotor retardation, coarse facial features and multiple congenital malformations such as aplasia or hypoplasia of thedistal phalanx or fifth finger nail. Additionally, cardiac, gastrointestinal, genitourinary or central nervous system malformations may be associated.

Composition: Anti-human BRG1 rabbit monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Immunogen: Synthetic peptide corresponding to the fraction of amino acids 200-300 of the mouse BRG1.

Name: Rabbit anti-human IgA Antibody (Polyclonal)

Description and aplications:Anti-IgA antibody reacts with surface immunoglobulin IgA alpha chains. It is useful when identifying leukemias, plasmacytomas, and B-cell lineage derived Hodgkin’s lymphomas. Due to the restricted expression of heavy and light chains in these diseases, demonstration of Bcell lymphoma/plasmacytoma is aided with this antibody.

Composition: Anti-human IgA rabbit polyclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with
0.2% BSA and 0.09% sodium azide

Name: Rabbit anti-human Neuron Specific Enolase (NSE) Polyclonal Antibody

Description and aplications: Enolase is a glycolytic enzyme catalyzing the reaction pathway between 2-phospho glycerate and phosphoenol pyruvate. In mammals, enolase molecules are dimmers composed of three distinct subunits (α,β and γ). The alpha-subunit is expressed in most tissues and the beta-subunit only in muscle. The gamma-subunit is expressed primarily in neurons, in normal and in neoplastic neuroendocrine cells. Co-expression of NSE and chromogranin A is common in neuroendocrine neoplasms.

Composition: Anti-human NSE rabbit polyclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with
0.2% BSA and 0.09% sodium azide

Immunogen: Synthetic peptide derived from Cterminus of human NSE.

Name: Rabbit anti-human PGP 9.5 Antibody (Polyclonal)

Description and aplications: This antibody recognises a molecule with a molecular mass of 27 kDa known as “Protein Gene Product 9.5” or PGP 9.5 and encoded by the UCHL1 (ubiquitin carboxy-terminal hydrolase L1 isoenzyme) gene, located in the chromosomal region 4p13. This protein catalyses the hydrolysis of ubiquitin’s C-terminal esters and amides, playing an important role in protein degradation. Overexpression of the UCHL1 gene occurs in several neoplasms, including leukaemias, carcinomas, and several tumours of mesenchymal origin. In normal tissues, PGP 9.5, which shows mainly a cytoplasmic staining pattern, is present in neurons and nerve fibres of the central and peripheral nervous systems, as well as in numerous neuroendocrine cells, except those of the digestive tract, of which only the pancreatic islets of Langerhans show consistent positive staining. Other normal tissues that are usually stained are segments of renal tubules, spermatogonias and Leydig cells, smooth muscle, and germinal centres.

Composition: anti-human PGP 9.5 rabbit polyclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Immunogen: Immunogen: Recombinant protein corresponding to the total length of human protein PGP 9.5.

Name: Rabbit anti-human Poly (ADP-Ribose) Polymerase 1 Antibody (Polyclonal)

Description and aplications: PARP (EC 2.4.2.30) is a nuclear protein with a molecular mass of 116 kDa and two zinc finger motifs which binds to DNA and specifically detects DNA nicks and breaks produced by different genotoxic agents. PARP catalises the ADP-ribosylation of proteins using NAD+ as a substrate. PARP activation is a consequence of ischemic injury and leads to intracellular depletion of NAD+, which can only be replaced by ATP consumption. Ischemia/Reperfusion (I/R) injury results in substantial DNA damage and cells need to consume large amounts of ATP to
sustain reparative poly-ADP-ribosylation. Proteolysis  of PARP to its stable 85-kDa fragment is an early marker of programmed cell death (apoptosis), mediated by caspase 3 or CPP32. Cleavage occurs between Adp216 and Gly217, a site in PARP conserved across species. This antibody reacts with human, mouse and rat PARP.

Composition:anti-human Poly (ADP-Ribose) Polymerase 1 rabbit polyclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Immunogen: Synthetic peptide derived from the Nterminal region of human protein PARP.

Specification:

Human cytomegalovirus (CMV) is a β-herpesvirus (human herpesvirus 5) that causes widespread persistent infection. CMV continues to be an important opportunistic pathogen in immunocompromised patients. It is estimated that 30% of transplant recipients experience CMV disease.1 The range of organ involvement in post-transplant CMV disease is wide; hepatitis occurs in 40% of liver transplant recipients2, and pneumonitis is more frequently seen in heart and heart-lung transplant patients.3 Other organs that are commonly affected are the gastrointestinal tract and the peripheral and central nervous systems. Histologic diagnosis of CMV in fixed tissues usually rests on identifying characteristic cytopathic effects including intranuclear inclusions, cytoplasmic inclusions, or both, especially in the endothelial cells. However, histologic examination lacks sensitivity, and in some cases atypical cytopathic features can be confused with reactive or degenerative changes.4 Additionally, up to 38% of patients with gastrointestinal CMV disease fail to demonstrate any inclusions.5 In these cases, IHC using monoclonal antibodies against early and late CMV antigens allows the detection of CMV antigens in the nucleus and cytoplasm of infected cells. In addition, IHC may allow detection of CMV antigens early in the course of the disease when cytopathic changes have not yet developed.6 Various CMV antigens can serve as IHC targets for the detection of CMV infection. During productive, lytic CMV infection, the viral genes, encoding these antigens, are expressed in a coordinated and temporal fashion. The first viral genes expressed at 3-12 hours post-infection are the immediate early (IE) genes, which control viral and cellular gene expression to optimize the host environment for the production of viral DNA.7 IE gene expression is followed by viral early (E) gene transcription, or delayed early or intermediate early genes, usually expressed at 12-24 hours post infection. The E genes encode for proteins that are involved in viral DNA replication. Finally, E gene expression is followed by the transcription of viral late genes. The late genes encode for virus structural proteins.7 The sensitivity of IHC for detecting CMV infection ranges from 78% to 93%.4-5 The sensitivity of IHC is better than light microscopic identification of viral inclusions and compares favorably with culture and in situ hybridization.6-9 Additionally, immunohistochemical assays can be completed faster than the shell vial culture technique, allowing for rapid results that are important for early anti-CMV therapy.10 Immunohistochemistry has been used to detect CMV infection in patients with steroid refractory ulcerative colitis, and the routine use of IHC for the detection of CMV in the evaluation of these patients is now recommended.11-12 CMV immunostaining has been used to detect occult CMV infection of the central nervous system in liver transplant patients who develop neurologic complications.13 It has also been used to demonstrate a high frequency of CMV antigens in tissues from first trimester abortions.14

Presentation:

The product is formulated in a phosphate saline buffer (0.01M, pH 7.2) containing 0.1% sodium azide preservative